Please login to the form below

natalizumab

This page shows the latest natalizumab news and features for those working in and with pharma, biotech and healthcare.

Novartis expands its generics franchise with natalizumab biosimilar

Despite the setback, Novartis is continuing to expand its generics division, with natalizumab its fifth proposed biosimilar in nine months.

Latest news

Roche sets disruptive price for new MS drug Ocrevus in US

remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).
Neurodegenerative disorders market set to reach $45bn by 2022

for Biogen's Tysabri (natalizumab) and Novartis' Gilenya (fingolimod).
Novartis drug works in secondary progressive MS

After years of disappointing trials in SPMS - most recently the failure of Biogen's Tysabri (natalizumab) - there are finally some optimistic signs that patients with progressive forms of MS could get
Biogen cuts workforce and culls pipeline projects

Among the pipeline casualties are Tecfidera for secondary progressive MS, and Biogen also reported yesterday that its injectable MS drug Tysabri (natalizumab) was unable to slow disability progression in this
Pfizer maintains lead in top CNS drug sales - just

Biogen's rise is predominately due to its growing share of the multiple sclerosis (MS) market, with strong sales for its established medicine Tsyabri(natalizumab) and more recent launches of two

More from news
Approximately 4 fully matching, plus 48 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
Pharma deals during February 2013

Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Michael Fleming joins biosimilars firm Coherus

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.
XenoPort appoints chief medical officer

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Covid-19: how is it affecting prescribing patterns?

Lemtrada is a monoclonal antibody (MAB) given by infusion. Tysabri, or natalizumab, is also an infusion injection.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...